HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Morepen Laboratories Ltd Stock Comparison

Alivus Life Sciences Ltd vs Morepen Laboratories Ltd Stock Comparison

Last Updated on: Jul 01, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 993.2 as of 01 Jul 09:50.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 22.4 on March 2024 . This represents a CAGR of 12.02% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore on March 2020 to ₹ 2149 crore on March 2024 . This represents a CAGR of 38.03% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Morepen Laboratories Ltd for the Mar '25 is ₹ 470.46 crore as compare to the Dec '24 revenue of ₹ 458.12 crore. This represent the growth of 2.69%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Mar '25 is ₹ 46.85 crore as compare to the Dec '24 ebitda of ₹ 41.48 crore. This represent the growth of 12.95%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 20.31 crore over 8 quarters. This represents a CAGR of 17.82% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Morepen Laboratories Ltd News Hub

News

Morpen Labs incorporates subsidiary in Dubai

The newly formed wholly owned subsidiary namely Morepen Labs ' FZCO, will trade in pharmac...

Read more

19 Jun 2025 08:44

News

Board of Morepen Laboratories approves availing of working capital loan of Rs 50 cr

The Board of Morepen Laboratories at its meeting held on 23 May 2025 has approved inter-al...

Read more

23 May 2025 10:25

News

Board of Morepen Laboratories notes incorporation of step-down subsidiary in Dubai

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decisio...

Read more

12 May 2025 18:29

News

Board of Morepen Laboratories recommends Final Dividend

Morepen Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

12 May 2025 16:11

News

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 Ma...

Read more

06 May 2025 11:55

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Morepen Laboratories Ltd?

Market cap of Alivus Life Sciences Ltd is 12,296 Cr while Market cap of Morepen Laboratories Ltd is 3,385 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Morepen Laboratories Ltd?

The stock performance of Alivus Life Sciences Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Morepen Laboratories Ltd?

As of July 1, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1002.7. On the other hand, Morepen Laboratories Ltd stock price is INR ₹61.78.

How do dividend payouts of Alivus Life Sciences Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions